Yorktown Management & Research Co Inc Purchases Shares of 6,600 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Yorktown Management & Research Co Inc purchased a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 6,600 shares of the company’s stock, valued at approximately $245,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Pacer Advisors Inc. boosted its position in Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock valued at $50,139,000 after buying an additional 1,347,775 shares during the period. Boston Trust Walden Corp boosted its position in Amphastar Pharmaceuticals by 81.4% in the 4th quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock valued at $36,347,000 after buying an additional 439,281 shares during the period. Geode Capital Management LLC boosted its position in Amphastar Pharmaceuticals by 1.5% in the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company’s stock valued at $44,674,000 after buying an additional 14,015 shares during the period. Portolan Capital Management LLC boosted its position in Amphastar Pharmaceuticals by 201.1% in the 3rd quarter. Portolan Capital Management LLC now owns 327,764 shares of the company’s stock valued at $15,906,000 after buying an additional 218,901 shares during the period. Finally, Nordea Investment Management AB boosted its position in Amphastar Pharmaceuticals by 4.8% in the 4th quarter. Nordea Investment Management AB now owns 279,714 shares of the company’s stock valued at $10,386,000 after buying an additional 12,851 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 7,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the transaction, the executive vice president now directly owns 118,469 shares of the company’s stock, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard K. Prins sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $48.80, for a total transaction of $244,000.00. Following the transaction, the director now directly owns 31,471 shares in the company, valued at $1,535,784.80. The trade was a 13.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,893 shares of company stock worth $1,329,570 in the last ninety days. 27.10% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ:AMPH opened at $33.19 on Wednesday. The company’s fifty day moving average price is $38.89 and its 200 day moving average price is $43.88. Amphastar Pharmaceuticals, Inc. has a 12 month low of $32.25 and a 12 month high of $56.45. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The firm has a market capitalization of $1.60 billion, a P/E ratio of 11.06, a P/E/G ratio of 1.07 and a beta of 0.81.

Analyst Ratings Changes

AMPH has been the topic of a number of analyst reports. Piper Sandler lowered shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $66.00 to $36.00 in a report on Tuesday. StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Finally, Wells Fargo & Company initiated coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective on the stock. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $50.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.